Catherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.
Here’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
While CAR T-cell therapy has been proven to work for liquid—or blood—cancers, the challenge has been to apply this technology to solid tumors.
Transplant eligibility issues and drug regimen options raise difficult questions when treating older multiple myeloma patients.
CAR T-cell therapies and other immunotherapy give this oncologist’s cancer patients hope for a better quality of life.
Unique partnerships between payers and providers focus on keeping patients out of the hospital and on the road to remission.
Moffitt Cancer Center expert shares her thinking on managing chemotherapy-related side effects.
Key takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.
Acute myeloid leukemia experts share promising new developments on the oncology horizon.
Physicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.